Personalis (PSNL) Stock
Genomics services firm for cancer research partners. Here's the price, business snapshot, and what's worth knowing about Personalis in October 2026.
Personalis, Inc. (PSNL) is a clinical‑stage genomics company that provides advanced DNA sequencing, bioinformatics and immune profiling services used in oncology research and personalised cancer programmes. Its offerings include tumour–normal sequencing, neoantigen discovery, and adaptive immune receptor profiling, sold to biopharma partners and research institutions. Investors should know Personalis primarily earns revenue from service contracts and collaborations rather than marketed therapeutics, so growth depends on partner adoption and demand for precision oncology tools. As a small‑cap biotechnology firm (market cap ≈ $848.64M), PSNL can offer upside if its assays and proprietary analytics gain broader uptake, but it also carries typical sector risks: funding needs, competition, reimbursement and regulatory uncertainty. Financial performance can be variable and future profitability is not guaranteed. This is general educational information and not personalised investment advice; consider your risk tolerance and review the company’s filings or consult a financial adviser before investing.
Personalis (PSNL) Stock Forecast
Analyst price target, next 12 months
$10.91
-33.0% vs today's $16.28
Price range over the last 12 months
Close to its 12-month high
Analysts covering Personalis have a consensus 12-month target of $10.91, below the current price of $16.28.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Personalis Inc. stock, expecting it to rise toward $10.91 soon.
Financial Health
PERSONALIS INC has stable revenue and cash flow, but low profit margins indicate challenges.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Precision Oncology Services
Demand for personalised cancer diagnostics and neoantigen discovery could drive revenue growth, though uptake and timing can vary and affect returns.
Proprietary Analytics Edge
Personalis’s bioinformatics and IP may differentiate its offering, but technological competition and execution risk remain important considerations.
Partner‑Led Growth
Revenue is often driven by collaborations with pharma and research centres, so progress depends on partner pipelines and commercial adoption.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
